Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5867 Articles

Douglas A. McIntyre | Oct 22, 2008 at 3:15 PM EDT

Amgen Becomes A Biotech Safety Stock (AMGN)

Amgen Inc. (NASDAQ: AMGN) has just posted earnings. The biotech giant for anemia treatments posted $1.09 GAAP EPS and adjusted…

Douglas A. McIntyre | Oct 22, 2008 at 9:24 AM EDT

Biotech Implosion: Dynavax (DVAX)

Dynavax Technologies Corp. (NASDAQ: DVAX) is the latest biotech implosion as shares are down some 75% today. The company gave…

Douglas A. McIntyre | Oct 21, 2008 at 6:14 AM EDT

Pfizer (PFE) Does Some Good, Viagra Rocks On

Once all of the one-time charges were washed out of the numbers, Pfizer recorded adjusted income of $4.2 billion, an increase…

Douglas A. McIntyre | Oct 20, 2008 at 7:48 AM EDT

Day Trader Alert: Syneron medical (ELOS)

Syneron Medical Ltd. (ELOS) is generally a thin volume stock, although it may see more active trading as the opening…

Douglas A. McIntyre | Oct 16, 2008 at 3:23 PM EDT

Gilead Boosted Partly By Currencies (GILD)

Gilead Sciences Inc. (NASDAQ: GILD) has just issued its third quarter earnings at $0.52 net EPS and $0.55 non-GAAP EPS…

Douglas A. McIntyre | Oct 14, 2008 at 3:10 PM EDT

Genentech Mixes Top-Line & Bottom-Line Numbers (DNA)

Genentech, Inc. (NYSE: DNA) today posted earnings of $0.81 per share and $3.408 billion in revenue. That’s below First Call…

Douglas A. McIntyre | Oct 14, 2008 at 11:16 AM EDT

Looking Beyond Genentech Earnings (DNA)

After today’s close, we are expecting the earnings report of of biotech giant Genentech, Inc. (NYSE: DNA). First Call estimates…

Douglas A. McIntyre | Oct 14, 2008 at 7:13 AM EDT

J&J Earnings: Size Does Matter (JNJ)

Johnson & Johnson (NYSE: JNJ) is showing that some companies can get it right despite tough times. The company has…

Douglas A. McIntyre | Oct 14, 2008 at 5:24 AM EDT

Merck (MRK): More Trouble With Vioxx

A lot of people believe that Merck (MRK) knew a lot more about the dangers of its arthritis drug Vioxx…

Douglas A. McIntyre | Oct 9, 2008 at 7:54 AM EDT

Can deCODE Genetics Escape Icelandic Woes? (DCGN)

If you think things are bad here in the U.S., Iceland is experiencing something far worse. The country is on…

Douglas A. McIntyre | Oct 6, 2008 at 5:52 PM EDT

Dendreon’s Move Still Leaves Many Questions (DNDN)

Dendreon Corp. (NASDAQ: DNDN) was an incredible performer today, and one which makes you wonder how well it would have…

Douglas A. McIntyre | Oct 6, 2008 at 8:40 AM EDT

Icahn Wins Blue Ribbon in ImClone Race (IMCL, LLY, BMY, MRK)

Carl Icahn appears to have won a blue ribbon for ImClone Systems (NASDAQ: IMCL) shareholders. The biotech stock is trading…

Douglas A. McIntyre | Oct 6, 2008 at 7:47 AM EDT

OSI Phase III Falls Short (OSIP, DNA)

OSI Pharmaceuticals Inc. (NASDAQ: OSIP) is getting hit hard in early trading this morning. The biotech has released data showing…

Douglas A. McIntyre | Oct 6, 2008 at 7:30 AM EDT

Biotech Implosion: CombinatoRx (CRXX)

CombinatoRx, Incorporated (NASDAQ: CRXX) is seeing its stock implode this morning. The company released data from its Phase IIb study…

Douglas A. McIntyre | Oct 1, 2008 at 9:52 AM EDT

Boston Scientific (BSX) Slaughters It Shareholders Again

The list of management screw-ups at Boston Scientific (BSX) is almost too long to number. It bought rival Guidant and…

1 … 346 347 348 349 350 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Amgen Becomes A Biotech Safety Stock (AMGN)

Biotech Implosion: Dynavax (DVAX)

Pfizer (PFE) Does Some Good, Viagra Rocks On

Day Trader Alert: Syneron medical (ELOS)

Gilead Boosted Partly By Currencies (GILD)

Genentech Mixes Top-Line & Bottom-Line Numbers (DNA)

Looking Beyond Genentech Earnings (DNA)

J&J Earnings: Size Does Matter (JNJ)

Merck (MRK): More Trouble With Vioxx

Can deCODE Genetics Escape Icelandic Woes? (DCGN)

Dendreon’s Move Still Leaves Many Questions (DNDN)

Icahn Wins Blue Ribbon in ImClone Race (IMCL, LLY, BMY, MRK)

OSI Phase III Falls Short (OSIP, DNA)

Biotech Implosion: CombinatoRx (CRXX)

Boston Scientific (BSX) Slaughters It Shareholders Again

What JEPQ Actually Paid the Last Time the Nasdaq Fell 10%: a Stress Test for Its 10% Yield

VOO Is About to Become the First $1 Trillion ETF, and SPY Holders Are Paying 3x More for the Same Index

Laid Off at 58 With a 401(k) Loan, She Thought She Had 60 Days to Replace the Money. The Tax Code May Give Her Much Longer.

Laid Off at 58 With a 401(k) Loan, She Thought She Had 60 Days to Replace the Money. The Tax Code May Give Her Much Longer.

IRMAA Surprise: How Your 401(k) Distribution Today Triggers Medicare Surcharges Two Years Later

XRP Price Prediction: Will XRP Ever Hit a New All-Time High?

What JEPQ Actually Paid the Last Time the Nasdaq Fell 10%: a Stress Test for Its 10% Yield

Health and Healthcare Articles

All Health and Healthcare Articles

Amgen Becomes A Biotech Safety Stock (AMGN)

Biotech Implosion: Dynavax (DVAX)

Pfizer (PFE) Does Some Good, Viagra Rocks On

Day Trader Alert: Syneron medical (ELOS)

Gilead Boosted Partly By Currencies (GILD)

Genentech Mixes Top-Line & Bottom-Line Numbers (DNA)

Looking Beyond Genentech Earnings (DNA)

J&J Earnings: Size Does Matter (JNJ)

Merck (MRK): More Trouble With Vioxx

Can deCODE Genetics Escape Icelandic Woes? (DCGN)

Dendreon’s Move Still Leaves Many Questions (DNDN)

Icahn Wins Blue Ribbon in ImClone Race (IMCL, LLY, BMY, MRK)

OSI Phase III Falls Short (OSIP, DNA)

Biotech Implosion: CombinatoRx (CRXX)

Boston Scientific (BSX) Slaughters It Shareholders Again

What JEPQ Actually Paid the Last Time the Nasdaq Fell 10%: a Stress Test for Its 10% Yield

VOO Is About to Become the First $1 Trillion ETF, and SPY Holders Are Paying 3x More for the Same Index

Laid Off at 58 With a 401(k) Loan, She Thought She Had 60 Days to Replace the Money. The Tax Code May Give Her Much Longer.

Featured Reads

Laid Off at 58 With a 401(k) Loan, She Thought She Had 60 Days to Replace the Money. The Tax Code May Give Her Much Longer.

IRMAA Surprise: How Your 401(k) Distribution Today Triggers Medicare Surcharges Two Years Later